SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Recursion Reports No New Safety Signals in Phase 2 REC-4881

The company reported 81% Grade 1/2 treatment-related adverse events (TRAEs), 15% Grade 3 TRAEs and no Grade 4/5 TRAEs.

RXRX

Related stories